Simply Wall St.
Is Viatris’ Shift Into Complex Therapies Altering The Investment Case For VTRS?
📊
AI Sentiment
Positive
6/10
- Home
- VTRS
VTRS
Viatris Inc.
as of 12-26-2025 3:44pm EST
$12.33
+$0.12
+0.97%
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
| Founded: | 1961 | Country: | United States |
| Employees: | N/A | City: | CANONSBURG |
| Market Cap: | 12.0B | IPO Year: | N/A |
| Target Price: | $11.50 | AVG Volume (30 days): | 8.2M |
| Analyst Decision: | Hold | Number of Analysts: | 6 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | -3.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.85 - $12.68 | Next Earning Date: | 11-06-2025 |
| Revenue: | $14,124,400,000 | Revenue Growth: | -6.14% |
| Revenue Growth (this year): | -2.23% | Revenue Growth (next year): | 1.18% |
AI-Powered VTRS Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 77.85%
77.85%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Viatris Inc. News
VTRS Breaking Stock News: Dive into VTRS Ticker-Specific Updates for Smart Investing
Simply Wall St.
Viatris (VTRS): Reassessing Valuation After Recent Share Price Gains and Evolving Investor Sentiment
📊
AI Sentiment
Positive
6/10
Compare VTRS vs Leading Stocks
See how VTRS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "VTRS Viatris Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.